Insider Buying: Neonc Technologies (NASDAQ:NTHI) CEO Acquires $85,000.00 in Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI – Get Free Report) CEO Amir Heshmatpour bought 20,000 shares of the stock in a transaction that occurred on Wednesday, November 11th. The stock was bought at an average cost of $4.25 per share, for a total transaction of $85,000.00. Following the transaction, the chief executive officer owned 3,333,000 shares of the company’s stock, valued at $14,165,250. The trade was a 0.60% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Neonc Technologies Stock Performance

NTHI traded up $0.06 on Friday, hitting $4.91. 251,853 shares of the company were exchanged, compared to its average volume of 118,828. The stock’s fifty day moving average is $3.30 and its 200-day moving average is $5.27. Neonc Technologies Holdings, Inc. has a 12 month low of $2.50 and a 12 month high of $11.38.

Neonc Technologies (NASDAQ:NTHI – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03).

Analysts Set New Price Targets

Several research firms have weighed in on NTHI. BTIG Research reiterated a “buy” rating and set a $15.00 price objective on shares of Neonc Technologies in a research report on Tuesday, September 8th. Zacks Research raised shares of Neonc Technologies from a “strong sell” rating to a “hold” rating in a report on Thursday, November 5th. Roth Capital assumed coverage on shares of Neonc Technologies in a research report on Thursday, September 24th. They set a “buy” rating on the stock. Wall Street Zen raised shares of Neonc Technologies from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Weiss Ratings downgraded shares of Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, October 21st. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Get Our Latest Research Report on Neonc Technologies

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE grew its stake in Neonc Technologies by 5.0% during the first quarter. Bank of America Corp DE now owns 235,396 shares of the company’s stock worth $1,650,000 after buying an additional 11,108 shares in the last quarter. Global Retirement Partners LLC bought a new stake in shares of Neonc Technologies during the 2nd quarter worth approximately $126,000. Marshall Wace LLP boosted its position in shares of Neonc Technologies by 423.5% during the 3rd quarter. Marshall Wace LLP now owns 114,046 shares of the company’s stock worth $388,000 after acquiring an additional 92,262 shares in the last quarter. Westmount Partners LLC boosted its position in shares of Neonc Technologies by 355.2% during the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after acquiring an additional 153,858 shares in the last quarter. Finally, BlackRock Inc. acquired a new stake in shares of Neonc Technologies during the 2nd quarter worth approximately $815,000.

About Neonc Technologies

(Get Free Report)

NeOnc Technologies Holdings, Inc. is a biotechnology company developing treatments for brain tumors and other central nervous system cancers. Its research focuses on approaches intended to deliver therapies to the brain, where the blood-brain barrier can limit the effectiveness of conventional treatments. The company’s pipeline includes NEO100, a formulation of perillyl alcohol designed for intranasal delivery, and NEO212, a compound combining perillyl alcohol with temozolomide. These candidates are being developed for potential use in brain cancer treatment.

Read More

Insider Buying and Selling by Quarter for Neonc Technologies (NASDAQ:NTHI)

Receive News & Ratings for Neonc Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neonc Technologies and related companies with MarketBeat.com's FREE daily email newsletter.